key: cord-0904704-j20ve3kj authors: Otaif, Wael; Al Somali, Abdulaziz Ismail; Al Habash, Ahmed title: Episcleritis as a possible presenting sign of the novel coronavirus disease: A case report date: 2020-09-08 journal: Am J Ophthalmol Case Rep DOI: 10.1016/j.ajoc.2020.100917 sha: 1e347199cd9f548485a76118e36c9b30a892f04f doc_id: 904704 cord_uid: j20ve3kj PURPOSE: In this report, we describe a case of episcleritis that appeared to be the first sign of the novel coronavirus disease (COVID-19). OBSERVATIONS: A 29-year-old man with no prior medical condition presented with a complaint of redness and foreign body sensation in his left eye, which started two days before his consultation. He had no history of decreased vision, pain, photophobia, discharge, ocular surgery, or trauma. He had no symptoms in his fellow eye nor did he have any systemic symptoms. External examination of his left eye revealed a sectoral nasal conjunctival and episcleral injection and a clear cornea. There was no scleral edema. A diagnosis of episcleritis was made based on clinical grounds and topical fluorometholone 0.1%. was started. Three days later, the patient presented with headache, shortness of breath, cough, and fever (39.2 °C). Real-time fluorescence polymerase chain reaction test of his nasopharyngeal swab returned a positive result for COVID-19. The patient was then admitted for observation and supportive therapy. After five days, fever, respiratory and ocular symptoms were markedly improved and the patient was discharged and advised to isolate at home for 14 days. CONCLUSIONS AND IMPORTANCE: This is the first report that describes episcleritis as a possible presenting sign of COVID-19. Understanding the association between ocular signs/symptoms and COVID-19 can aid in the diagnosis of the viral infection and can help in limiting its transmission. The coronavirus disease (COVID-19) was initially reported in Wuhan City (Hubei Province, China) in December 2019, and has since spread worldwide causing a global pandemic. This disease is caused by a novel virus known as the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 1 . SARS-CoV-2 can be transmitted via respiratory droplets that come in contact with the mucosal surface of the mouth, nose, or eyes 2 . Although COVID-19 primarily involves the respiratory tract, involvement of the gastrointestinal tract and ocular tissues has been reported 3, 4 . A recent case report illustrated that SARS-CoV-2 RNA can be detected in the conjunctival swab of a confirmed COVID-19 patient; this finding indicates that viral conjunctivitis can be one of the early signs of COVID-19 5 . Additionally, a number of reports suggested that patients who had SARS-CoV-2 infection presented with conjunctivitis as the first symptom after contact with a confirmed COVID-19 patient 6, 7 . However, only a limited number of researches have been conducted to elaborate the impact of SARS-CoV-2 infection on the ocular tissues 8 . To the best of our knowledge, this is the first report describing a case of episcleritis as a possible presenting sign of COVID-19. A 29-year-old man with no prior medical condition presented with a complaint of redness and foreign body sensation in his left eye, which started two days before his consultation. He had no history of decreased vision, pain, photophobia, or discharge; he also had no prior history of similar condition, ocular surgery or trauma. He had no symptoms in his fellow eye nor did he have any systemic symptoms. External examination of his left eye revealed a sectoral nasal conjunctival and episcleral injection and a clear cornea. (Fig. 1) . There was no scleral edema. A diagnosis of episcleritis was made based on phenylephrine blanching test which was performed using 10% phenylephrine hydrochloride; the results showed blanching of the engorged conjunctival and superficial episcleral vessels. Intraocular pressure was 17mmHg in the affected eye, and the fundus examination was unremarkable. The patient was prescribed a topical preservative-free lubricant along with fluorometholone ophthalmic suspension, USP 0.1% (FML®, Allergan, Inc, Irvine, CA, USA) four times a day for one week. Three days later, the patient reported headache, shortness of breath, cough, and fever (39.2°C). Real-time fluorescence J o u r n a l P r e -p r o o f polymerase chain reaction test of his nasopharyngeal swab returned a positive result for COVID-19. The patient was then admitted for observation and supportive therapy was initiated consisting of vitamin supplements, oral azithromycin 500mg once daily, and oral paracetamol 1g three times per day, in addition to topical fluorometholone 0.1% treatment. After five days, fever, respiratory and ocular symptoms were markedly improved and the patient was discharged and advised to isolate at home for 14 days. The present case illustrates episcleritis as a possible first manifestation of COVID-19. Based on our scientific literature review, this is the first report of episcleritis as the first presenting sign of COVID-19. Episcleritis is a common and self-limiting inflammatory condition of the episclera. Most cases of episcleritis are idiopathic in nature; however, an association between episcleritis and systemic disease has found in less than one third of patients who have episcleritis 9 . Episcleritis has also been described as an ocular manifestation of viral diseases like Ebola, herpes zoster, and hepatitis C [10] [11] [12] Written consent to publish this case has not been obtained. This report does not contain any personal identifying information. All those designated as authors should meet all four criteria for authorship, and all who meet the four criteria should be identified as authors. For more information on authorship, please see http://www.icmje.org/recommendations/browse/roles-andresponsibilities/defining-the-role-of-authors-and-contributors.html#two. All listed authors meet the ICMJE criteria. We attest that all authors contributed significantly to the creation of this manuscript, each having fulfilled criteria as established by the ICMJE. We confirm that the manuscript has been read and approved by all named authors. We confirm that the order of authors listed in the manuscript has been approved by all named authors. The Corresponding Author declared on the title page of the manuscript is: This author submitted this manuscript using his/her account in EVISE. We understand that this Corresponding Author is the sole contact for the Editorial process (including EVISE and direct communications with the office). He/she is responsible for communicating with the other authors about progress, submissions of revisions and final approval of proofs. We confirm that the email address shown below is accessible by the Corresponding Author, is the address to which Corresponding Author's EVISE account is linked, and has been configured to accept email from the editorial office of American Journal of Ophthalmology Case Reports: Evaluation and Treatment Coronavirus (COVID-19) The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak-An update on the status Enteric involvement of coronaviruses: is faecaloral transmission of SARS-CoV-2 possible? The severe acute respiratory syndrome coronavirus in tears Ocular manifestations of a hospitalised patient with confirmed 2019 novel coronavirus disease Important coronavirus updates for ophthalmologists -American Academy of Ophthalmology 2019-nCoV transmission through the ocular surface must not be ignored The evidence of SARS-CoV-2 infection on ocular surface Diagnosis and Treatment of Episcleritis and Scleritis Ocular Complications in Survivors of the Ebola Outbreak in Guinea Herpes zoster eye complications: Rates and trends Hepatitis C virus as a systemic disease: reaching beyond the liver Episcleritis as an ocular manifestation in a patient with COVID-19 Characteristics of Ocular Findings of Patients with Coronavirus Disease Ocular manifestations of coronavirus disease 2019. Graefe's Arch Clin Exp Ophthalmol 2020 No funding or grant support. The following authors have no financial disclosures: WO, AS, and AH All authors attest that they meet the current ICMJE criteria for Authorship Acknowledgements None J o u r n a l P r e -p r o o f [Instructions: Please check all applicable boxes and provide additional information as requested.] No conflict of interest exists.We wish to confirm that there are no known conflicts of interest associated with this publication and there has been no significant financial support for this work that could have influenced its outcome. No funding was received for this work. Not applicable. Written consent to publish this case has not been obtained. This report does not contain any personal identifying information. The International Committee of Medical Journal Editors (ICMJE) recommends that authorship be based on the following four criteria:1. Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; AND 2. Drafting the work or revising it critically for important intellectual content; AND 3. Final approval of the version to be published; AND 4. Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.